A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 20 May 2016 Status changed from suspended to recruiting.